Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | CTSG | P08311 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.51 |
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.47 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694578 | 0.89 | TAAR1 (0.52) | TAAR1CTSGCMA1PTGER1PTGER4 | |
| SCHEMBL5846778 | 0.87 | TAAR1 (0.50) | TAAR1CTSGCMA1PNMTTSHR | |
| SCHEMBL27918718 | 0.86 | TAAR1 (0.57) | TAAR1CTSGCMA1PNMTTSHR | |
| SCHEMBL11349111 | 0.85 | TAAR1 (0.55) | TAAR1CTSGCMA1PNMTTSHR | |
| SCHEMBL30288127 | 0.84 | FFAR1 (0.59) | TAAR1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL455219 | 0.84 | FFAR1 (0.59) | TAAR1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL3591795 | 0.83 | TAAR1 (0.46) | TAAR1CTSGCMA1PTGER1PTGER4 | |
| SCHEMBL27503091 | 0.83 | FFAR1 (0.48) | PTGER1PTGER4PTGER3PTGER2FFAR1 | |
| SCHEMBL6612012 | 0.83 | PTGER1 (0.50) | CTSGCMA1PTGER1PTGER4PTGER3 | |
| SCHEMBL13235696 | 0.83 | IAPP (0.56) | TAAR1CTSGCMA1PNMTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| WO-2012168458-A1 | ZWITTERIONIC COMPOUNDS USEFUL AS CATALYSTS FOR ESTERIFICATION REACTIONS AND PROCESSES FOR THEIR PRODUCTION | ECOSYNTH BVBA (BE) | 2012-12-13 | — | — | WO | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| CN-101712675-A | Nitrogenous benzheterocycle derivate and application thereof to treating nervous and mental diseases | JIANGSU GUOHUA INVEST CO LTD | 2010-05-26 | — | — | CN | disclosed |
| EP-1326849-B1 | BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE | MERCK SHARP & DOHME (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-6995155-B2 | Benzodiazepine derivatives as inhibitors of gamma secretase | MERCK SHARP & DOHME LIMITED (GB) | 2006-02-07 | — | — | US | disclosed |
| US-20050119252-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-06-02 | — | — | US | disclosed |
| WO-2005042516-A2 | LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040024203-A1 | Benzodiazepine derivatives as inhibitors of gamma secretase | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1326849-A1 | BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE | Merck Sharp & Dohme Limited (GB) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030912-A1 | BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE | MERCK SHARP & DOHME LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| US-5677306-A | ANTAGONIZING ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID RECEPTOR, USEFUL FOR TREATING ALL ISCHEMIAS | RHONE-POULENC RORER S.A. (FR) | 1997-10-14 | — | — | US | disclosed |
| EP-0001002-B1 | INDANAMINES, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1981-08-12 | — | — | EP | disclosed |
| EP-0001002-A1 | Indanamines, processes for their preparation and compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-03-07 | — | — | EP | disclosed |
| US-4128666-A | PHENYLETHANOLAMINE N-METHYL-TRANSFERASE INHIBITORS | SMITHKLINE CORPORATION (US) | 1978-12-05 | — | — | US | disclosed |
| US-4096173-A | Chlorinated 1-aminoindane N-methyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119252-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | MC3R, MC1R, MC4R | TAAR1 153/4885CTSG 2005/4885CMA1 934/4885 |
| US-20040024203-A1 | Benzodiazepine derivatives as inhibitors of gamma secretase | BACE1, BACE2, PSEN1 | TAAR1 1062/4885CTSG 495/4885CMA1 1009/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | TAAR1 524/4885CTSG 4386/4885CMA1 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.